BlackBerry (NASDAQ:BBRY): Morgan Stanley has lowered its rating on BlackBerry to Equal Weight from Overweight, due to weaker than expected traction in BB10. The price target is kept at $11, and the analyst points out that it is the third downgrade for the company today.
Barrick Gold (NYSE:ABX): BMO Capital now rates Barrick at Underperform, down from Market Perform, following the Pascua Lama project delay and potential impairments of $4.5-$5 billion. The price target has also been lowered from $30 to $17.
Biogen (NASDAQ:BIIB): Citing the strength of the U.S. launch for Tecfidera, Piper Jaffray has raised its price target for Biogen to $251 from $229, although the firm continues to see risk for to Tecfidera’s NAS status in Europe even after the CHMP gave Sanofi’s Aubagio the status. Piper keeps a Neutral rating on the shares.
Qihoo 360 (NYSE:QIHU): Stifel has increased its target on Qihoo to $55 from $49, based on what the firm sees as the company’s accelerating revenue growth and innovation. The firm notes that the company is launching a new mobile search engine and two Wifi wireless router models in order to address mobile Internet user needs, and keeps a Buy rating on the stock.